anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prospective cohort study of the clinical course of HIV-1 infection occurring after candidate HIV-1 vaccination (breakthrough infection) with ALVAC-HIV (vcP1521) and AIDSVAX B/E in reference to study NCT00223080 RV144. This study will enroll volunteers who become HIV-infected during the course of follow up in a phase III preventive HIV vaccine trial conducted in Rayong and Chon Buri, Thailand. Volunteers will be enrolled in this protocol to provide additional long-term follow up to establish whether differences in viral load after infection (comparing vaccine to placebo) are associated with altered disease outcomes, as well as provide more detailed immunologic and virologic assessment of these volunteers.

After enrollment in RV152, follow-up visits were scheduled at 0, 1, 3, and 6 months, and every 3 months thereafter. After month 12, CD4+ T cell counts and viral load were obtained at 6-month intervals until the CD4+ T cell count declined to \<350/ul or highly-active antiretroviral therapy (HAART) was initiated, at which time CD4+ T cell counts and viral load were obtained every 3 months. Peripartum antiretroviral drugs given for prevention of mother-to-child-transmission was not considered a study endpoint, however HAART initiated during pregnancy and continued post-partum was counted. After a single CD4+ T-cell count \< 350/ul a second sample was requested about 2 weeks later, and if the confirmatory measurement was \>350/ul, a study endpoint was not registered and the volunteer resumed a normal visit schedule. A single genital fluid collection for viral load was obtained at the first RV152 visit. Clinical and laboratory data from RV144, including CD4+ T-cell and HIV-1 plasma viral load measurements, were linked to RV152 to inform primary and secondary protocol analyses as well as volunteer care and treatment.
PURPOSE: To provide a polishing and hand-cleaning material composed of a waterless hand cleanser free from polishing particles and applied to a supporting member for polishing. CONSTITUTION: This polishing and hand-cleaning material is composed of a supporting member having a polishing face and capable of absorbing and holding a fluid and a non-polishing water-based hand cleanser absorbed to the supporting member. The hand cleanser is composed of a solvent and/or a surfactant. The cleaning action is attained by the solvent or the surfactant and the polishing cleaning action is attained by the polishing face of the supporting member. A towel cloth is used as the supporting member. A plurality of such towels are dispensed in the form of a continuously wound roll put into a selectively sealable hermetic vessel. The user can be take out a towel cloth containing a proper amount of cleanser by opening the lid of the vessel.
BACKGROUND: Hand-sewn anastomosis and stapled anastomosis are the 2 main types of gastrojejunal anastomotic methods in pancreaticoduodenectomy. There is ongoing debate regarding the most effective anastomotic method for reducing delayed gastric emptying after pancreaticoduodenectomy. This study aims to identify factors that influence delayed gastric emptying after pancreaticoduodenectomy and assess the impact of different anastomotic methods on delayed gastric emptying.
METHODS: The study included 1,077 patients who had undergone either hand-sewn anastomosis (n = 734) or stapled anastomosis (n = 343) during pancreaticoduodenectomy between December 2016 and November 2021 at our department. We retrospectively analyzed the clinical data, and a 1:1 propensity score matching was performed to balance confounding variables.
RESULTS: After propensity score matching, 320 patients were included in each group. Compared with the stapled anastomosis group, the hand-sewn anastomosis group had a significantly lower incidence of delayed gastric emptying (28 [8.8%] vs 55 [17.2%], P = .001) and upper gastrointestinal tract bleeding (6 [1.9%] vs 17 [5.3%], P = .02). Additionally, the hand-sewn anastomosis group had a significantly reduced postoperative length of stay and lower hospitalization expenses. However, the hand-sewn anastomosis group had a significantly longer operative time, which was consistent with the analysis before propensity score matching. Logistic regression analysis showed that stapled anastomosis, intra-abdominal infection, and clinically relevant postoperative pancreatic fistula were independent prognostic factors for delayed gastric emptying.
CONCLUSION: Hand-sewn anastomosis was associated with a lower incidence rate of clinically relevant delayed gastric emptying after pancreaticoduodenectomy. Stapled anastomosis, intra-abdominal infection, and clinically relevant postoperative pancreatic fistula could increase the incidence of postoperative clinically relevant delayed gastric emptying. Hand-sewn anastomosis should be considered by surgeons to reduce the occurrence of postoperative delayed gastric emptying and improve patient outcomes.
PURPOSE:A solution of isosorbide nitrate, containing the isosorbide nitrate and an acid amide, having improved solubility in water, and useful for preventing and treating angina pectoris. CONSTITUTION:A solution containing isosorbide nitrate, e.g. isosorbide nitrate, isosorbide 2- or 5-mononitrate, and an acid amide. The solution is obtained by adding 0.1-50W/V% one or two or more selected from the group consisting of nicotinic acid amide, isonicotinic acid amide, acetamide and N,N-dimethylacetamide as the acid amide to the solution. The solution obtained by the above- mentioned method has the following features: A high concentration of isosorbide is contained, and fine crystals thereof will not be deposited on mixing with water. The danger can be avoided in the preparation thereof. Thus, the solution is advantageous to the preparation and the use thereof.
Systems, methods, and other embodiments associated with a graphical user interface for scheduling clinical staff are described. In one embodiment, a method includes generating a schedule for a plurality of events. The plurality of events are events for one or more clinical studies. Generating the schedule includes defining an order and an amount of time for each event of the plurality of events. The method also includes automatically generating a graphical user interface (GUI) from the schedule by displaying the plurality of events on a timeline grouped into shifts. The GUI displays conflicts between the shifts.
Conventional ET + PDAT. PDAT will be carried out with diode laser with optical fibre coupled to the equipment (660 nm, 100 mW, 20 s). The photosensitizer used will be methylene blue.
An exercise system using a plurality of exercise cycles with the users applying user exercise force at user exercise speed. The exercise system includes a display displaying user indicators moving along respective paths of travel on the display simulating the movement of cycles therealong. The paths of travel are displayed to simulate the travel of a plurality of cycles racing against each other. The exercise system further includes a display control measuring the exercise speed of the plurality of users applied to their respective exercise cycles, and determining the applied cumulative exercise efforts of the users. The display control also determines a lead user based upon which of the users has the greatest cumulative exercise effort, and determines when the cumulative exercise effort of particular ones of the users are within a preselected range less than the cumulative exercise effort of the lead user. While the cumulative exercise effort of the particular users remains within the preselected range and in response thereto, the display control adjusts upward the cumulative exercise effort of the particular users by predetermined amounts. The display control controls movement of the user indicators along their respective paths of travel on the display, with the displayed movement of the user indicators along their respective paths of travel being indicative of their respective adjusted cumulative exercise efforts. The user indicators of the particular users are caused to travel along their respective paths of travel in a manner corresponding to the upwardly adjusted exercise efforts of the particular users, thereby giving the particular users an advantage over the lead user.
This open, prospective, observational multicenter cohort study aims to study the efficacy, safety and effective concentration of Posaconazole tablets for prevention of pulmonary fungal infection in patients with hematopoietic stem cell transplantation. A total of 360 hematopoietic stem cell transplantation patients receiving Posaconazole tablets are expected to be enrolled. Posaconazole tablets will be taken orally from the day of transplantation (300 mg Q12h D1) followed by 300 mg Qd, until 90 days after transplantation. The total duration of the study is estimated to be 24 months, with each patient participating for an estimated 3 months. The relationships between UGT1A4\*3 genotype and drug serum concentration, IFD incidence, Aspergillus infection rate, IFD-related mortality rate, IFD-free survival rate, and overall survival rate will be used to evaluate the effectiveness of Posaconazole tablets in preventing invasive pulmonary fungal infection in patients with hematopoietic stem cell transplantation. Safety of Posaconazole tablet will be validated by the overall incidence and severity of adverse events in patients.
In vitro studies have shown that lanthanum binds phosphate in the physiologically relevant pH range of 3 to 7. In simulated gastric fluid, lanthanum binds approximately 97% of the available phosphate at pH 3-5 and 67% at pH 7, when lanthanum is present in a two-fold molar excess to phosphate. Bile acids have not been shown to affect the phosphate binding affinity of lanthanum. In order to bind dietary phosphate, lanthanum carbonate chewable tablets must be administered with or immediately after meals.

In five phase 1 pharmacodynamic studies comparing the reduction from baseline of urinary phosphorus excretion in healthy volunteers (N=143 taking lanthanum carbonate), it was shown that the mean intestinal phosphate binding capacity of lanthanum ranged from 235 to 468 mg phosphorus/day when lanthanum was administered at a dose of 3 g per day with food. By comparison, in one study with an untreated control group (n=10) and another study with a placebo group (n=3), the corresponding mean changes from baseline were 3 mg phosphorus/day and 87 mg phosphorus/day, respectively.

In healthy subjects, lanthanum carbonate oral powder and lanthanum carbonate chewable tablets produce similar effects on urinary phosphate excretion.
BACKGROUND: Our systematic review aimed to critically evaluate empirical literature describing the association of muscle-strengthening exercise (MSE) with recurrence and/or mortality among breast cancer survivors.
METHODS: We included English-language empirical research studies examining the association between MSE and recurrence and/or mortality among females diagnosed with breast cancer. Seven databases (MEDLINE, PsycINFO, Embase, Scopus, Web of Science, Cochrane CENTRAL, and CINAHL) were searched in September 2023. Quality was appraised using the Mixed Methods Appraisal Tool. Results are summarized descriptively.
RESULTS: Five sources were identified. MSE measurement differed in relation to the description of the MSE (i.e., muscle-strengthening vs. strength training), examples of activities (e.g., sit-ups or push-ups vs. calisthenics vs. circuit training), and exercise frequency (i.e., days vs. times/week). Findings offer provisional evidence that some MSE may lower the hazards of recurrence and mortality. This association may vary by race, weight status, and menopausal status.
CONCLUSIONS: In summary, limited available evidence suggests that MSE may lower the hazards of recurrence and mortality. More consistent measurement and analyses would help generate findings that are more readily comparable and applicable to inform clinical practice. Further research is needed to improve understanding of the strength and differences of these associations among underserved and underrepresented women.
We describe a regulated antigen delivery system (RADS) that has (a) a vector  that includes (1) a gene encoding a desired gene product operably linked to a control sequence, (2) an origin of replication conferring vector replication  using DNA polymerase III, and (3) an origin of replication conferring vector  replication using DNA polymerase I, where the second origin of replication i s operably linked to a control sequence that is repressible by a repressor. Th e RADS microorganism also has a gene encoding a repressor, operably linked to an activatible control sequence. The RADS described provide high levels of the desired gene product after repression of the high copy number origin of replication is lifted. The RADS are particularly useful as live bacterial vaccines. Also described is a delayed RADS system, in which there is a delay  before the high copy number origin is expressed after the repression is lifted. The delayed RADS is also particularly useful for live bacterial vaccines. Also described are several control elements useful for these systems, as well as methods for providing immunity to a pathogen in a vertebrate immunized with the RADS microorganisms.
Each subject who passed the screening is immunized with Plasmodium vivax 1-5 × 10\^6, observe the time when the parasite is detected in the peripheral blood of the subjects after inoculation, the change of the parasite density in the peripheral blood of the whole treatment cycle (about 6 weeks) and the control effect of the drug on the parasite density. The clinical symptoms and signs after treatment are mainly observed; Blood routine, blood biochemistry, blood coagulation, tumor markers and other laboratory test indicators change; Changes of cellular immunity and humoral immunity; Changes in quality of life. When Plasmodium infected erythrocytes among total erythrocytes (defined as the parasite density) ≥ 0.1% occurs during the test, artemisinin drugs should be used to control the parasite density below 0.1%, and symptomatic treatment should be carried out. The duration of Plasmodium immunotherapy for each subject is 6 weeks (time window, ± 1 day). The day the immunodynamic marker (Fim) is greater than baseline level is defined as the first day of Plasmodium immunotherapy. When Plasmodium immunotherapy lasts for 6 weeks (time window, ± 1 day), use antimalarial drugs to kill the parasite and terminate the treatment. After treatment, the patients are followed up for 2 years. We will carry out a follow-up visit once a month after the termination of Plasmodium infection according to the plan, and the follow-up visit in the first month, third month and sixth month is outpatient visit, which is ± 5 days in the first month and ± 7 days in the third month and sixth month respectively; Follow-up outpatient visit will be conducted every 3 months ± 10 days; The rest are telephone follow-up (once every 30 days ± 5). When the follow-up time overlaps with the previous outpatient follow-up time, no additional telephone follow-up will be conducted.
The invention provides a composition capable of improving sleep, and belongs to the field of medicines or health-care foods. The composition comprises the following components in parts by weight: 10-30 parts of theanine, 40-60 parts of gamma-aminobutyric acid, 10-30 parts of spina date seed extract, 0.2-0.3 part of astaxanthin and 1-3 parts of magnesium gluconate. The composition further comprises: 5-20 parts of medlar, 5-15 parts of rhizoma polygonati, 5-10 parts of passion flower, 5-30 parts of mulberry, 5-20 parts of maca, 3-20 parts of ginseng, 0.2-0.5 part of sea cucumber peptide, 0.1-0.6 part of oyster peptide, 5-15 parts of black ginger, 1-5 parts of deer heart blood and 5-20 parts of cinnamon. The invention also provides a preparation method of a pharmaceutical preparation or a health food and a health product prepared from the composition. The invention also provides application of the composition, the pharmaceutical preparation or the health food. The composition can obviously improve insomnia, improve sleep quality and has the effects of nourishing brain and soothing nerves.
A treatment compound for hoof disease in an animal has a base material and treatment agent. The base material is wax, resin, paste, polymer, oil, or creme. The treatment agent is zinc, copper, oxytetracycline, or tetracycaline. The treatment compound is applied to a hoof area and has a high viscosity in the range of 100,000 to 2,000,000 centipoises to retain the treatment compound on the hoof in a normal animal environment. The treatment compound can be applied by brush, spray, roller, or dipping. The treatment compound is curable by air or UV light to provide a durable, robust shell. The treatment compound can be applied to an interior surface of a boot which is disposed over the hoof to retain the treatment compound on the hoof in normal animal environments. The boot is color coded to indicate length of time that the boot has been applied.
Prodn. of stable anhydrous lactose is carried out by extruding dry crystalline alpha-lactose hydrate (I) in an extruder whose casing is heated to >100 degrees C. The process is pref. carried out using a Battenfeld-type screw extruder in which the gap between the screw and the casing gradually decreases and the material is subjected to increasing shear in a controlled manner. The H2O released is allowed to evaporate off as the lactose emerges from the extruder. The prod. is suitable for use as a carrier for the mfr. of pharmaceutical tablets or capsules. The process gives a non-hygroscpoi prod. with a moisture content of 1wt.%.
This study has the aim to continue the provision of DRV and rtv to pediatric patients that continue to benefit from treatment with it after participation in any of three ongoing pediatric studies sponsored by Tibotec Pharmaceuticals. In addition, information on the safety of DRV and rtv in combination with other antiretroviral therapies will be assessed. At the baseline visit, inclusion and exclusion criteria will be checked to confirm eligibility. Once eligible, patients will continue treatment either on the once daily dose regimen (when coming from the TMC114-TiDP29-C230 study) or a twice daily regimen (when coming from the TMC114-C212 or TMC114-TiDP29-C228 studies). Assessments and visit frequency will take place as per local standard of care but are desirable every 3 months. The interval between two visits should not exceed 6 months. Pregnancy testing for girls having had their first menses is foreseen. In addition, it is desirable that testing includes efficacy assessments (immunology and plasma viral load) and laboratory safety assessments (hematology, biochemistry including pancreatic amylase (if available) or lipase and lipid analysis). Serious Adverse Events and certain selected Adverse Events will be collected. Treatment will be continued until one of the following criteria is met (whichever occurs first): Virologic failure, treatment limiting toxicity, loss to follow-up, withdrawal of consent or assent by the patient or withdrawal of consent by the caregiver, pregnancy, termination of the trial by the sponsor, when Darunavir becomes commercially available, is reimbursed or can be accessed through another source (as there are access program or government program) in the region the patient is living in. The sponsor advises participating centers to plan the study visits every 3 months but frequency will depend on local practice and standard of care. The sponsor has also foreseen in the study protocol a guidance on specific safety assessments to be performed as well as detailed instructions on how to deal with specific toxicities and undesirable effects. However local practice will prevail and the assessments performed may vary depending on the region the patient is participating in. Intake of study medication will happen once daily or twice daily, depending on what the patient took in the original pediatric trial. For the twice daily regimen, the regimen may be adjusted as the patient gains weight. The adult dosage regimen of 600/100 mg DRV/rtv may be administered as of 40 kg of body weight. Depending on the history of the patient, following dosages may be administered: DRV oral suspension (100mg DRV/ml), DRV tablets 75 mg, 150 mg, 600 mg, all for twice daily intake. DRV 400 mg for the once daily 800 mg intake (2 tablets per intake).DRV intake will be combined with rtv in oral suspension (80 mg rtv/ml), capsule or tablet (both 100 mg).
The present invention includes a spray drying disposable device for use in a spray drying system. The disposable has a spray drying head and a plasma drying chamber. The head has a spray dry nozzle assembly in fluid communication with the plasma source and the pressurized aerosol gas source. The pressurized gas flows in a vortex pattern that atomizes plasma droplets in the chamber. The head also includes a plenum has uniform air pressure of the drying gas. A baffle plate forms the floor of the plenum having drying gas jets that supply drying gas to the chamber. The atomized plasma droplets evaporate in the presence of the drying gas emitted from the jets to obtain dried plasma particles and humid air. A capture filter captures the dried plasma particles and allows the humid air to pass. The humid air passes through the gas outlet and the exhaust port.
There is a higher risk of esophageal and gastric varices bleeding in cirrhosis patients with moderate and severe esophageal and gastric varices. Once there is a high mortality rate of esophageal and gastric varices bleeding, it will cause great losses to the family and society. Therefore, it is of great social and economic significance to prevent esophageal and gastric varices bleeding through economic and effective methods. As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal. The application of carvedilol can reduce the pressure of portal vein, and when the portal hypertension is improved, the imbalance of intestinal mucosal barrier and flora will also be changed. Berberine can regulate the intestinal flora, which is safe and effective in clinical application. Gastroscopy is still the main method of screening varicose veins. We can determine whether there is GOV in patients and evaluate the risk of varicose vein bleeding. However, gastroscopy can only observe the situation in the digestive tract lumen, and ultrasound endoscopy can scan the outside of the tube wall, so as to more comprehensively evaluate the change of portal hypertension. The purpose of this study is to apply endoscopic ultrasonography to the whole process of the study, which can be used as a more sensitive means to observe the changes of portal hypertension, and to systematically evaluate the continuous changes of portal hypertension. It provides a theoretical basis and measurement means for a more comprehensive and scientific evaluation of portal hypertension.In this study, the patients with GOV who need primary prevention were randomly divided into two groups. Carvedilol or carvedilol combined with berberine were given for 12 months respectively. The degree of varicose vein relief was judged by ES and EUS, and the changes of oral and intestinal flora were detected at the same time To understand the possible mechanism of carvedilol and berberine in reducing portal hypertension.